Controversy and perspective in the management of marginally operable stage IIIA non-small cell lung cancer: response to Editorial by Charlotte Billiet and Dirk De Ruysscher and Editorial by Dr. Wanpu Yan and Dr. David R. Jones

Physicians in the world never stop pursuing the best approach for patients. We are pleased to participate in a debate on what is the most optimal management for stage IIIA non-small cell lung cancer (NSCLC), which is well known for heterogeneity of diseases and complexity of treatment options.